US › Healthcare

Pacific Biosciences of California (PACB)

US · Healthcare · Medical Devices

$1.44+1.41%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$37.2M
Revenue YoY
+0.1%
Net profit
$-8.3M
Profit YoY
+98.1%
EPS
$-0.12
EPS estimate
$-0.13
Net margin
-22.3%

EPS came in at -0.12 against a street estimate of -0.13 — a beat of 7.7%.

Key statistics

Market cap
$441.1M
Forward P/E
0.0
P/B
183.13
Book value
$0.01
EPS (TTM)
$-0.41
52-week high
$2.73
52-week low
$1.09
50-day MA
$1.45
200-day MA
$1.71
Beta
2.32

Analyst view

Analysts rate Pacific Biosciences of California a buy (6 buy, 8 hold, 0 sell out of 14) with an average price target of $2.46.

Shareholding

Insiders
8.77%
Institutions
53.76%

Largest institutional holders

FundStake
ARK Investment Management LLC11.68%
BlackRock Inc8.14%
SoftBank Group Corp6.59%
Vanguard Group Inc5.49%
Vanguard Capital Management, LLC4.12%
Amova Asset Management Americas, Inc2.27%
Sumitomo Mitsui Trust Group Inc2.27%
Geode Capital Management, LLC2.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pacific Biosciences of California — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.